Research of novel biocompatible radiopaque microcapsules for arterial embolization

Int J Pharm. 2013 Aug 16;452(1-2):211-9. doi: 10.1016/j.ijpharm.2013.05.001. Epub 2013 May 22.

Abstract

Embolic agents, such as microparticles, microspheres or beads used in current embolotherapy are mostly radiolucent, which means the agents are invisible under X-ray imaging during and after the process of embolization, and the fate of these particles cannot be precisely assessed. In this research, a radiopaque embolic agent was developed by encapsulating lipiodol in polyvinyl alcohol. The lipiodol-containing polyvinyl alcohol microcapsules (LPMs) were characterized and evaluated for their morphology, size distribution, lipiodol content, lipiodol release, elasticity, and deliverability through catheter. The radiopacity of LPMs in vials and in living mice was both detected by an X-ray imaging system. The biocompatibility of LPMs was investigated with L929 cells and in mice after subcutaneous injection. Embolization of LPMs to a rabbit kidney was performed under digital subtraction angiography (DSA) and the radiopacity of LPMs was verified by computed tomography (CT).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiography, Digital Subtraction
  • Animals
  • Arteries
  • Biocompatible Materials / administration & dosage
  • Biocompatible Materials / chemistry
  • Capsules
  • Catheterization
  • Contrast Media / administration & dosage*
  • Contrast Media / chemistry
  • Elasticity
  • Embolization, Therapeutic
  • Ethiodized Oil / administration & dosage
  • Ethiodized Oil / chemistry
  • Female
  • Kidney / metabolism
  • Mice
  • Particle Size
  • Polyvinyl Alcohol / administration & dosage*
  • Polyvinyl Alcohol / chemistry
  • Rabbits
  • Tomography, X-Ray Computed

Substances

  • Biocompatible Materials
  • Capsules
  • Contrast Media
  • Ethiodized Oil
  • Polyvinyl Alcohol